The current generation of antibodies has done more than make a few companies rich. It has laid the groundwork for ambitious companies to move to maturity.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Evans, D. & Das, R. Monoclonal Antibodies: Evolving into a $30 Billion Market (DataMonitor, London, UK, 2005).
Mitchell, P. Next generation monoclonals less profitable than trailblazers? Nat. Biotechnol. 23, 906 (2005).
Presta, L. Antibody engineering for therapeutics. Curr. Opin. Struct. Biol. 13, 519–526 (2003).
Lu, D. Simultaneous blockade of both the epidermal growth factor receptor and the insulin-like growth factor receptor signaling pathways in cancer cells with a fully human recombinant bispecific antibody. J. Biol. Chem. 279, 2856–2865 (2004).
Author information
Rights and permissions
About this article
Cite this article
Baker, M. Upping the ante on antibodies. Nat Biotechnol 23, 1065–1072 (2005). https://doi.org/10.1038/nbt0905-1065
Issue Date:
DOI: https://doi.org/10.1038/nbt0905-1065